title: [Intracranial hemorrhages: epidemiology and implication of antithrombotic therapy].
abstract: OBJECTIVE
  Intracranial hemorrhage (ICH) is an antithrombotic treatment complication. Our study's goal is to assess the proportion of ICH occurring while the patient is on antithrombotic treatment. The secondary goal is to assess the proportion of "avoidable" ICH (anticoagulant overdosage, debatables indications).
  
  
  METHODS
  We conducted a descriptive epidemiological single-center study of ICH during 2 years. We analyzed the type of ICH, the type of antithrombotic treatment, the level of anticoagulation and the relevance of antithrombotic treatment indication.
  
  
  RESULTS
  Of the 400 patients admitted for an ICH, 131 (33%) were treated by antithrombotic therapy: oral anti-vitamin K anticoagulants (VKA) in 14.1% of cases and antiplatelet agents in 15.1%. Of VKA patients, overdosage rate was 30.2%. The indication of antithrombotic therapy was debatable in 18.3% of cases.
  
  
  CONCLUSIONS
  Our study highlights the frequency of ICH occurring on antithrombotic therapy and the significant proportion of "avoidable" ICH.
authors.affiliation: Unité Neurovasculaire, CHU, Saint-Étienne, France. jvarvat@9online.fr
authors.forename: Jérôme
authors.initials: J
authors.lastname: Varvat
authors.forename: Magali
authors.initials: M
authors.lastname: Epinat
authors.forename: Christophe
authors.initials: C
authors.lastname: Nuti
authors.forename: Jean-Christophe
authors.initials: JC
authors.lastname: Antoine
authors.forename: Patrick
authors.initials: P
authors.lastname: Mismetti
authors.forename: Pierre
authors.initials: P
authors.lastname: Garnier
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000925:Anticoagulants / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D015897:Comorbidity; D062787:Drug Overdose; D005260:Female; D006801:Humans; D020300:Intracranial Hemorrhages / Q000139:chemically induced / Q000453:epidemiology* / Q000517:prevention & control; D008297:Male; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D012189:Retrospective Studies; D012307:Risk Factors; D019851:Thrombophilia / Q000188:drug therapy; D014812:Vitamin K / Q000037:antagonists & inhibitors
chemical_list: D000925:Anticoagulants; D010975:Platelet Aggregation Inhibitors; D014812:Vitamin K